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Background: The purpose of the study was to determine the relationship between high sensitivity C-reactive
protein (hs-CRP) levels and prognostic factors in chronic obstructive pulmonary disease.
Methods: We studied 50 stable COPD patients with: spirometry, 6 minute walk distance, body mass index, GOLD
stage (spirometric classification) and smoking status. In these patients hs-CRP values were measured and compared
with those of 50 healthy controls. Then the serum hs-CRP was subjected to evaluation for any correlation with the
predictors of outcomes in COPD subjects.
Results: Hs-CRP levels were higher in COPD patients than in controls (4.82 vs. 0.88 mg/L p < 0.01). Correlation was
found between hs-CRP and the following variables: FEV1 (r= −0.813; p < 0.01), 6MWD (r= −0.876; p < 0.01), body
mass index (r= −0.710; p < 0.01), GOLD stage (r= 0.797, p < 0.01) and smoking status (r= 0.796; p < 0.01). Using
multivariate analysis, FEV1 and 6MWD showed the strongest negative association with hs-CRP levels.
Conclusions: The circulating levels of the inflammatory marker hs-CRP are significantly elevated in patients with
COPD, supporting the view that COPD is in part an inflammatory disorder. Hs-CRP levels in stable COPD patients
are best correlated with FEV1 and 6-minute walk distance (6MWD). This information should be considered when
hs-CRP levels are measured in stable COPD patients.
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Chronic obstructive pulmonary disease (COPD) is a syn-
drome characterised and defined by a single physiological
parameter: limitation of expiratory air-flow which, most
often, is slowly progressive over the years [1]. According
to the widely accepted definition from Global Initiative on
Obstructive Lung Disease (GOLD) COPD is "a disease
state characterized by airflow limitation that is not fully
reversible. The airflow limitation is usually progressive
and associated with an abnormal inflammatory response
of the lungs to noxious particles and gases" [2]. For the
first time this definition encompasses the idea that
COPD is a chronic inflammatory disease and much of* Correspondence: akhtar.jamal10@gmail.com
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reproduction in any medium, provided the orthe recent research has focused on the nature of this in-
flammatory response. Numerous studies performed in
recent years provide overwhelming evidence of COPD
as a condition characterized by an abnormal inflammatory
response beyond the lungs with evidence of low-grade
systemic inflammation which causes systemic manifes-
tations such as weight loss, skeletal muscle dysfunction,
an increased risk of cardiovascular disease, osteoporosis
and depression, among others [3-6]. Blood markers,
such as IL-6, CRP and fibrinogen have attracted interest
during recent years, and further studies in this area will
probably increase the understanding of systemic manifes-
tations in COPD [7].
One of the inflammatory markers which is increasingly
evaluated in COPD patients is C-reactive protein (CRP)
[8]. C-Reactive Protein (CRP) is an acute phase protein
synthesized predominantly by the hepatocytes in re-
sponse to tissue damage or inflammation. It has beenl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical and physiologic characteristics of the
COPD and control group
Control group COPD group P
Age(yrs) 53.65 ± 8.68 54.00 ± 7.58 0.628
M:F ratio 44:6 44:6 0.546
BMI(kg/m2) 22.55 ± 1.98 22.82 ± 2.63 0.679
FEV1(%) 88 ± 3.46 57.54 ± 18.33 0.000
6MWD(mtrs) 375.45 ± 68.98 212.60 ±53.22 0.000
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flow obstruction [6]. There are various studies evaluating
the relationship between CRP levels and other clinical var-
iables known to predict outcome in patients with COPD.
The present study aims to evaluate the levels of high
sensitivity CRP (hs-CRP) in patients with COPD and to
study the relationship between hs-CRP levels and prog-
nostic factors in COPD patients.
Methods
The present study was conducted at the Department of
Medicine, JN Medical College Hospital, AMU, Aligarh
from January 2008 to June 2009. The permission for the
study was taken from ethical committee. A total of 100
subjects, including 50 control and 50 patients of chronic
obstructive pulmonary disease (COPD), were recruited
in the study.
Patients who had dyspnea, chronic cough, sputum
production and risk factors, such as tobacco use and
occupational exposures to dust and chemicals with all
degree of airflow severity were consecutively included if
they had a postbronchodilator FEV1/FVC of <0.7 after
400 micrograms of inhaled salbutamol. Patients were
clinically stable (no exacerbation for 2 months) at the
time of evaluation. An informed consent was obtained
from each subject prior to entering the study.
Patients were excluded if they had a history of asthma
and/or the FEV1 increased more than 12% or 200 ml fol-
lowing inhalation of 400 μg salbutamol, if they had acute
coronary syndromes, collagen vascular/autoimmune dis-
eases, malignancy, pulmonary embolism, renal insuffi-
ciency, cirrhosis and other serious liver diseases and if
they were on steroid treatment.
A detailed history and physical examination was car-
ried out for every subject who entered in the study as
per a pre-designed proforma, including thorough phys-
ical examination, assessment of vital parameters, anthro-
pometry (height, weight, BMI) and systemic examination
for assessing the signs of COPD and also the presence of
any exclusion criteria as previously discussed.
We evaluated the following variables known to predict
outcome in COPD: degree of airflow obstruction by
FEV1, exercise capacity by the six minute walk distance
(6MWD) and body mass index (BMI). We also recorded
if patients were active smokers or quitters (those who
had left smoking ≥1 year).
BMI was calculated as the weight in kilograms divided
by height in meters2. The hs-CRP estimation was
performed by using UBI MAGIWEL CRP-quantitative
AD-401 kit, a solid phase enzyme linked immunosorbent
assay (ELISA) as per instructions of the manufacturer
(supplied with kit) with reference range for CRP
being 0.0-0.8 mg/dl. All patients underwent physiologic
evaluation that included measurement of the forcedexpiratory volume in 1-second (FEV1) and forced vital
capacity (FVC) using a spirometer (P. K. Morgan LTD,
Kent, England) with published predicted values. Quality
control and procedures of lung function testing were
performed according to the European Respiratory Society
guidelines. The 6MWD test carried out in a corridor 50 m
long. Statistical analysis was performed using SPSS version
10.0 Statistical package for Windows (SPSS, Chicago, IL).
Continuous variables were expressed as mean ± standard
deviation (Gaussian distribution) or range. Unpaired and
paired t tests for independent and dependent samples were
used to compare continuous data between two groups.
ANOVA or analysis of variance with Scheffe’s post hoc
analysis were used for comparing data between groups.
Linear relationship between variables was analyzed using
Pearson’s correlation coefficient and significance of ‘r’ was
tested. A Stepwise multivariate regression analysis was used
to study the determinants of CRP. All p values were two
tailed and values of < 0.05 were considered to indicate
statistical significance. All confidence intervals were calcu-
lated at 95% level.
Results
The study recruited 50 patients of with COPD (44 males
and 6 females). We also recruited 50 healthy, non smok-
ing subjects (44 males, 6 females) from the general
population of similar age and location. Most of patients
were in GOLD stages II and III and 76% of them were
still smoking. The clinical and physiologic characteristics
of the COPD and control group are presented in Table 1.
Distribution of subjects according to GOLD stage(spiro-
metric classification) and smoking status is shown in
Tables 2 and 3.
Mean value of hs-CRP in control group was 0.88 ±
0.48 mg/l (range: 0.2-1.8 mg/l) while 4.82 ± 1.97 mg/l
(range: 1.7-8.1 mg/l) in COPD group. When compared
with controls by independent samples t-test, the mean
value of hs-CRP was significantly higher in patients with
COPD (11.574, p < 0.01) (Figure 1).
Pearson’s correlation coefficient showed that (Table 4)
hs-CRP levels significantly correlated with GOLD
stage (r = 0.797; p < 0.01). A significant negative cor-
relation of hs-CRP was found with body mass index
(r = −0.710; p < 0.01), FEV1 (r = −0.813; p < 0.01) and
Table 2 Distribution of subjects according to GOLD stage
(spirometric classification)
GOLD stage No. of subjects Percentage (%)
Stage I 6 12
Stage II 22 44
Stage III 17 34
Stage IV 5 10
CONTROL CASE
STUDY GROUP
Figure 1 Showing CRP levels in COPD and control subjects.
Table 4 Pearson’s correlation of hs-CRP with other
variables
Correlation coefficient(r) P Sig. (2-tailed)
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significantly higher in smokers as compared to quitters
(r = 0.796; p < 0.01). There was no correlation of hs-
CRP with sex. Spearman’s correlation was used to find
out the correlation of hs-CRP with sex, smoking status
and GOLD stage.
Multistep linear regression analysis using hs-CRP as
dependent variable in COPD subjects
Multistep linear regression analysis was done on 50 sub-
jects using hs-CRP as the dependent variable and age,
BMI, FEV1, 6MWT, smoking status and GOLD stage as
covariates. The statistical details of the model are shown
in Table 5.
Stepwise multiple regression analysis was conducted to
find out significant predictors of hs-CRP. 6MWT and
FEV1 entered hierarchically in the regression model as
significant predictors of hs-CRP.
Discussion
Our study showed that the circulating levels of hs-CRP
were significantly elevated in patients with COPD com-
pared with controls (4.8 vs. 0.8 mg/l) (t=11.574, p < 0.01).
The main finding of our study is that CRP level in stable
COPD patients has the strongest association with
6MWD and FEV1. We also found that CRP levels corre-
lated independently with other important prognostic
clinical variables: namely BMI and GOLD stage(spiro-
metric classification). Some studies have demonstrated
elevated levels of CRP and fibrinogen in patients with
COPD [9,10] and a meta-analysis by Gan et al. con-
firmed a significant increase in CRP levels in COPD pa-
tients compared with controls indicating a persistent
systemic inflammation in subjects with COPD [4]. Yende
et al. reported a higher level of serum CRP in cases with
an obstructive pattern in their spirometry (3.5 mg/l) in
comparison to normal population (2.5 mg/l) (p < 0.0001)Table 3 Distribution of subjects according to smoking
status
Smoking status No. of subjects Percentage (%)
Smokers 38 76
Quitters 12 24
Total 50 100[8]. In a study conducted by Broekhuizen et al., stable
COPD patients had increased levels of inflammatory
markers like CRP [11]. F. Karadag, found out that serum
CRP was significantly higher in stable COPD patients than
in control subjects (p < 0.001) [12]. This study confirms
that circulating CRP levels are higher in stable COPD pa-
tients and may thus be regarded as a valid biomarker of
low-grade systemic inflammation.
In our study, hs-CRP was found to be significantly
higher in smokers as compared to quitters (r = 0.796;
p < 0.01). Our work duplicates the previous finding of
Juan P de Torres et al. regarding higher CRP levels in those
COPD patients who are active smokers compared with
those who are not [13,14]. Unfortunately, this effect could
not be confirmed in the control group because we only
recruited non-smoking individuals to represent the “nor-
mal” population. However, the level of CRP in the ex-
smoking COPD population remained significantly higher
than in the non-smoking control group. In contrast to the
above findings, Pinto-Plata et al., showed a significantly
higher level of CRP in COPD patients (50.03 ± 1.51 mg/l)Hs-CRP(mg/l) 1.000 0.
Smoking status .796 0.000
Sex -.019 0.877
BMI(kg/m2) -.710 0.000
FEV1 (%) -.813 0.000
6MWD(m) -.876 0.000
GOLD stage .797 0.000
Table 5 Multistep linear regression model
Model Variables R R2 β T P
1 6MWT 0.888 0.789 - 0.888 - 15.937 0.000
2 6MWT 0.934 0.873 - 0.497 - 6.805 0.000
FEV1 −0.487 −6.662 0.000
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trol groups (2.24 ± 1.04 mg/l) (p < 0.001) [6].
The authors suggest that, although cigarette smoking
has a role in promoting inflammatory process in COPD
patients, it is not the leading cause of increased inflam-
matory markers. It should be noticed that only some
cases develop inflammatory reaction following cigarette
smoking, and this can be due to genetic differences.
In our study, CRP is inversely correlated with FEV1. In
assessing the association between hs- CRP and lung
function, Shaaban et al., looked at cross-sectional and
longitudinal changes between CRP and FEV1 decline
[15]. Their analysis included 531 subjects demonstrating
a negative association between FEV1 and CRP(p = 0.002)
and higher CRPlevels over time were associated with a
faster FEV1 decline. Similarly, a recent study found CRP
levels associated with accelerated decline in FEV1 and
mortality in patients with mild to moderate COPD, indi-
cating that CRP measurements might enable identifica-
tion of patients at a high risk of disease progression and
mortality [16].
We observed that CRP levels are inversely correlated
with 6MWD. Koechlin et al., found that CRP levels
were inversely correlated with endurance time and
Broekhuizen et al., also found that CRP increases in
those patients with poor exercise capacity [11,17]. The
study by Pinto Plata and colleagues takes these findings
one step further. They evaluated 88 patients with COPD
and 71 controls and subjected them to extensive physio-
logical testing and a detailed review of medications.
Consistent with the results reported by Broekhuizen
et al. they found that serum CRP levels were inversely
related to the distanced achieved in the 6MWD inde-
pendent of other factors such as age, sex and smoking
history [6].
One of the important extrapulmonary manifestations
of COPD is skeletal muscle dysfunction and wasting
[18]. With increasing severity of disease, patients with
COPD lose muscle bulk, especially in their thighs and
upper arms. Over time, these patients lose exercise en-
durance and complain of fatigue and dyspnea with only
a minimal degree of exertion [19]. These symptoms cur-
tail their ability to exercise and compromise their cardiac
fitness, which further limits their exercise tolerance, cre-
ating a vicious downward spiral that can eventually lead
to generalized debility and immobility [20]. Indeed, some
authors postulate that the skeletal muscle dysfunction isa direct consequence of the systemic effects of the dis-
ease [21] whereas others propose that the “myopathy” is
an independent process that contributes to the systemic
inflammatory load of the disease [22]. Whatever the
mechanism, our results indicate that measuring CRP
levels in stable conditions could indirectly reflect the ex-
ercise capacity of these patients, an important prognostic
factor of the disease. Encouragingly, early interventions
with exercise programmes may restore some of the lost
health status related to muscle dysfunction and increase
patients' exercise tolerance and stamina. Collectively,
these studies have extended our concept of COPD be-
yond the pulmonary system, provided a solid clinical
and epidemiological rationale for linking systemic in-
flammation with peripheral muscle dysfunction and
raised the possibility of using anti-inflammatory treat-
ment to mitigate systemic inflammation in the hope of
improving health outcomes in these patients.
Interestingly, in our study, BMI is inversely correlated
inversely with CRP. This contrasts with the study by
Marie-Kathrin Breyer et al., who found that obese COPD
patients (BMI ≥ 30 kg/m2) were 3.3 times more likely
(95% CI, 1.5-7.0, p = 0.002) to have highly elevated CRP
levels compared to normal weight (BMI 21-24.9 kg/m2)
COPD patients, after taking clinically relevant con-
founders into account [23]. In contrast, COPD patients
with a low BMI (<21 kg/m2) were 2 times less likely
(OR, 0.5; 95% CI, 0.3-0.9, p = 0.022) to have highly ele-
vated CRP levels compared to normal-weight peers.
Schols et al., observed high CRP level in a special subset
of 16 COPD patients with high resting energy expend-
iture (REE) and low fat free mass (FFM) [24]. More
studies are needed to help resolve these controversial
findings. It has been proposed that inflammatory cyto-
kines could be secreted by adipocytes and by inflamma-
tory cells present in adipose tissue [25]. Further research
is needed to elucidate the effect of different cytokines on
body composition and vice versa.
Regarding the severity of disease based on GOLD cri-
teria (spirometric classification), the mean serum CRP
level was found to be significantly increased in severe
cases. Pinto-Plata et al. [6] showed that there was no sig-
nificant difference between the severity of disease and
serum CRP level but de Torres and co-workers [13] indi-
cated that serum CRP level significantly increased with
the aggravation of disease. Therefore, although we ex-
pect the inflammatory process to be worse and the in-
flammatory markers to be increased by increasing the
severity of disease, more studies are required in this
regard.
Conclusions
In summary, our study confirms that C-reactive protein
levels are increased in stable chronic obstructive
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ated with important clinical variables that help in
predicting outcome of the patients. Among them, the
most important are FEV1 and 6MWD. This finding rein-
forces and supports the relevance of CRP measurement
and we suggest that the information here presented
should be considered when CRP levels are measured in
stable COPD patients. Further follow up cohort studies
with greater samples and measuring CRP levels pro-
spectively should help to determine the validity of our
findings.
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